This perspective reflects themes consistently raised by senior leaders across UK wholesale distribution. It is not an argument for higher prices in isolation-but for a system that no longer mistakes fragility for efficiency.

An industry view from the middle of the medicines supply chain

The uncomfortable truth wholesalers see every day

From the outside, UK medicines shortages are often framed as operational failures, isolated manufacturing problems, or sudden spikes in demand. From the wholesaler’s position in the centre of the supply chain, the reality looks very different.

The most persistent pressures facing UK medicines supply today are not clinical, logistical, or even regulatory. They are economic. And they are structural.

For wholesalers, the challenge is no longer how to move medicines efficiently from manufacturer to pharmacy. It is whether the system still supports the existence of a sustainable, stable distribution layer at all.

A market that no longer behaves like a cycle

Historically, the UK generic medicines market has been cyclical. Prices fall, margins compress, supply tightens. Then shortages emerge, prices rise, manufacturers return, and stability resumes-at least temporarily.

What has changed over the last 18-24 months is not the cycle itself, but its duration and depth.

The downcycle has lasted longer than any in recent memory. Prices have remained depressed for extended periods. Cost inflation has continued relentlessly. And there are no clear signals that recovery will arrive before further structural damage occurs.

For wholesalers, this raises a fundamental question: is this still a cycle-or has the market reset to a new, unsustainable normal?

The penny problem and the collapse of pricing signals

One of the most misunderstood dynamics in the system is the obsession with marginal price reductions.

Pharmacies, under extreme funding pressure, are incentivised to chase every available penny of buying margin. Automated order management and cascade systems amplify this behaviour, driving prices down in real time across multiple wholesalers.

From a wholesaler’s perspective, this creates an impossible environment:

  • Paying a penny too much means stock cannot be sold

  • Prices can change multiple times within days

  • Forecasting becomes meaningless

  • Holding buffer stock becomes a financial risk, not a safeguard

The irony is stark. Driving prices down by a penny often reduces total margin across the system once reimbursement adjusts. Yet the behaviour persists because survival is measured in weeks, not years.

The result is not efficiency. It is the erosion of any reliable pricing signal.

Why “shortage” is often the wrong word

A critical distinction wholesalers see-often lost in public debate-is the difference between true shortages and economically driven supply withdrawal.

Many products now classified as “in shortage” are not absent from the system. They are simply unavailable at the tariff price.

Manufacturers pause supply because selling below cost is not sustainable. Wholesalers cannot stock product they cannot sell. Pharmacies refuse to order items that will dispense at a loss.

The medicine exists. The economics do not.

This is why traditional indicators-such as the number of products on concession-no longer reliably reflect physical supply disruption. Concession has become a proxy for tariff failure, not scarcity.

Volatility is rewarded; stability is penalised

Perhaps the most perverse outcome of the current system is what it rewards.

Stable, dependable supply chains-where manufacturers invest, wholesalers hold stock, and pharmacies dispense reliably-are financially punished.

Volatility, by contrast, creates opportunity. Shortages generate price spikes. Early access to constrained supply can produce temporary margin relief.

No participant enters the system to exploit instability. Yet the incentives increasingly push behaviour in that direction.

From the wholesaler’s seat in the middle, it is clear: the system does not pay for resilience. It pays for reaction.

The quiet consequences: service erosion and risk transfer

As margins erode, wholesalers are forced to reassess what they can afford to provide.

Service models built for a higher-margin era-multiple daily deliveries, deep geographic coverage, significant inventory buffers-become increasingly difficult to justify.

Every cost pressure pushes risk further downstream:

  • Less stock held centrally

  • Faster stock turns

  • Reduced tolerance for price uncertainty

These changes rarely make headlines, but they directly affect pharmacies’ ability to obtain medicines consistently-and patients’ ability to receive them without disruption.

Why reshoring and structural reform won’t work alone

There is growing policy interest in reshoring manufacturing and increasing domestic capacity. While well intentioned, wholesalers see a hard truth:

Without changes to pricing and reimbursement, none of this will work.

Domestic manufacturing at higher cost cannot survive in a market that rewards the lowest possible price at all times. Investment follows economic signals. At present, the signal is to exit, not to build.

What wholesalers believe must change

From within the system, several principles are clear:

  • A sustainable supply chain requires acceptance that prices must sometimes rise

  • Reimbursement volatility damages every layer of the market

  • Pharmacy funding pressure is a root cause, not a side effect

  • Removing or reforming blunt mechanisms such as clawback would reduce distortion

  • Stability should be valued as an outcome-not treated as a cost

None of these changes benefit wholesalers alone. They benefit the entire medicines ecosystem.

A warning from the middle

Wholesalers occupy a unique vantage point. They see manufacturers withdrawing quietly. They see pharmacies struggling to manage risk. They see policy responses arriving too late to prevent foreseeable outcomes.

When medicines disappear, it rarely comes without warning.

The signals are already visible-in pricing behaviour, supplier exits, and shrinking tolerance for risk.

Ignoring those signals does not prevent shortages.

It simply ensures they arrive with greater force, higher cost, and fewer options for recovery.